Summary statistics - qualitative results

(Groups: measurement principle)

EQA round: AIM2/20 - Autoimmunity

Deadline: 26.10.2020

Key: >>> ... marks correct (expected) result
> ... marks conditionally correct (acceptable) result
± ... marks the result not evaluated

N ... number of the results
Nrel ... relative number of the results

Test Sample	Group		N	Result	N_{rel}
Set 1					
(560) ANA screening (cell nucleus) - prove					
A1	(1) Fluorescent methods		1	Negative	1,3 %
			2	Inconclusive result (borderline)	2,6 %
		>>>	67	Positive	87 %
	(2) EIA methods		6	Negative	7,8 %
		>>>	1	Positive	1,3 %
	Total per sample: n = 77	Success: 88 %			
B1	(1) Fluorescent methods	>>>	70	Negative	91 %
	(2) EIA methods	>>>	7	Negative	9,1 %
	Total per sample: n = 77	Success: 100 %			
Total success: 88 %					
(572) ANA screening (cell nucleus) - semi-quantity					
A1	(0) Not specified	±	6	titre 40	9,1 %
		±	10	titre 80	15 %
		±	26	titre 160	39 %
		±	15	titre 320	23 %
		±	6	titre 640	9,1 %
		±	2	titre 1280	3,0 %
		±	1	titre 2560	1,5 %
	Total per sample: n = 66	Success (only evaluated results): evaluation			
B1	(0) Not specified	±	45	titre 0 (not measurable)	68 %
		±	14	titre 40	21 %
		±	6	titre 80	9,1 %
		±	1	titre 2560	1,5 %
	Total per sample: n = 66	Success (only evaluated results): evaluation			
(561) ANA - type of fluorescence - nucleus					
A1	(0) Not specified	±	1	No fluorescence	1,5 %
		±	20	Coarse speckled	29 %
		±	2	Coarse speckled; Fine speckled	2,9 %
		±	2	Coarse speckled; Nuclear matrix	2,9 %
		±	28	Fine speckled	41 %
		±	12	Nuclear matrix	18 %
		±	2	Nuclear matrix; Coarse speckled	2,9 %
		±	1	Unknown type of fluorescence	1,5 %
	Total per sample: n = 68	Success (only evaluated results): evaluation			
B1	(0) Not specified	>>>	68	No fluorescence	100 %
	Total per sample: n = 68	Success: 100 %			
(563) ANA screening (cytoplasma) - prove					
A1	(1) Fluorescent methods	>>>	64	Negative	94 %
			1	Inconclusive result (borderline)	1,5 %
			3	Positive	4,4 %
	Total per sample: n = 68	Success: 94 %			
B1	(1) Fluorescent methods	>>>	67	Negative	99 %
			1	Positive	1,5 %
	Total per sample: n = 68	Success: 99 %			
Total success: 93 %					
(573) ANA screening (cytoplasma) - semi-quantity					
A1	(0) Not specified	±	39	titre 0 (not measurable)	62 %
		±	13	titre 40	21 %
		±	8	titre 80	13 %
		±	1	titre 160	1,6 %
		±	1	titre 320	1,6 %
		±	1	titre 2560	1,6 %
	Total per sample: n = 63	Success (only evaluated results): evaluation			
B1	(0) Not specified	±	41	titre 0 (not measurable)	65 %
		±	15	titre 40	24 %
		±	6	titre 80	9,5 %
		±	1	titre 2560	1,6 %
	Total per sample: n = 63	Success (only evaluated results): evaluation			
(564) ANA - type of fluorescence - cytoplasma					
A1	(0) Not specified	>>>	61	No fluorescence	94 %
			1	Fine speckled cytoplasmic pattern	1,5 %
			3	Diffusion cytoplasmic picture	4,6 %

Summary statistics - qualitative results

(Groups: measurement principle)

EQA round: AIM2/20 - Autoimmunity

Deadline: 26.10.2020

Test

Sample	Group		N	Result	N_{rel}
	Total per sample: n = 65	Success: 94 %			
B1	(0) Not specified	>>>	64	No fluorescence	98 %
			1	Diffusion cytoplasmic picture	1,5 %
	Total per sample: n = 65	Success: 98 %			

Total success: 92 %

Set 2

(565) ANCA imunofluorescence - prove

A2	(1) Fluorescent met. (ethanol)	>>>	49	Positive	78 %
	(2) Fluorescent met. (formalin)	>>>	6	Positive	9,5 %
	(99) Another measurement principle	>>>	8	Positive	13 %
	Total per sample: n = 63	Success: 100 %			
B2	(1) Fluorescent met. (ethanol)	>>>	49	Negative	78 %
	(2) Fluorescent met. (formalin)	>>>	6	Negative	9,5 %
	(99) Another measurement principle	>>>	8	Negative	13 %
	Total per sample: n = 63	Success: 100 %			

Total success: 100 %

(574) ANCA IF (ethanol) - semi-quantity

A2	(0) Not specified	±	1	Not specified	1,9 %
		±	4	titre 20	7,4 %
		±	5	titre 40	9,3 %
		±	9	titre 80	17 %
		±	12	titre 160	22 %
		±	13	titre 320	24 %
		±	5	titre 640	9,3 %
		±	3	titre 1280	5,6 %
		±	2	titre 2560	3,7 %
	Total per sample: n = 54	Success (only evaluated results): evaluation			
B2	(0) Not specified	±	35	titre 0 (not measurable)	65 %
		±	19	titre 20	35 %
	Total per sample: n = 54	Success (only evaluated results): evaluation			

(578) ANCA IF (formalin) - semi-quantity

A2	(0) Not specified	±	1	Not specified	1,9 %
		±	4	titre 20	7,5 %
		±	8	titre 40	15 %
		±	8	titre 80	15 %
		±	14	titre 160	26 %
		±	12	titre 320	23 %
		±	2	titre 640	3,8 %
		±	2	titre 1280	3,8 %
		±	2	titre 2560	3,8 %
	Total per sample: n = 53	Success (only evaluated results): evaluation			
B2	(0) Not specified	±	34	titre 0 (not measurable)	64 %
		±	19	titre 20	36 %
	Total per sample: n = 53	Success (only evaluated results): evaluation			

(566) ANCA - type of fluorescence

A2	(0) Not specified	>>>	56	Perinuclear fluorescence	90 %
		>>>	6	Perinuclear fluorescence; ANA	9,7 %
	Total per sample: n = 62	Success: 100 %			
B2	(0) Not specified		1	Not specified	1,6 %
		>>>	61	No fluorescence	98 %
	Total per sample: n = 62	Success: 98 %			

Total success: 98 %

(569) anti-myeloperoxidase

A2	(1) Fluorescent methods	>>>	1	Positive	1,4 %
	(2) EIA methods		1	Inconclusive result (borderline)	1,4 %
		>>>	48	Positive	67 %
	(5) LIA, ILMA		1	Negative	1,4 %
		>>>	9	Positive	13 %
	(6) Immunoblotting	>>>	11	Positive	15 %
	(99) Another measurement principle	>>>	1	Positive	1,4 %
	Total per sample: n = 72	Success: 97 %			
B2	(1) Fluorescent methods	>>>	1	Negative	1,4 %
	(2) EIA methods	>>>	49	Negative	68 %
	(5) LIA, ILMA	>>>	9	Negative	13 %
			1	Positive	1,4 %
	(6) Immunoblotting	>>>	11	Negative	15 %
	(99) Another measurement principle	>>>	1	Negative	1,4 %
	Total per sample: n = 72	Success: 99 %			

Summary statistics - qualitative results

(Groups: measurement principle)

EQA round: AIM2/20 - Autoimmunity

Deadline: 26.10.2020

Test Sample	Group		N	Result	N_{rel}
Total success: 97 %					
(570) anti-proteinase III					
A2	(1) Fluorescent methods	>>>	1	Negative	1,4 %
	(2) EIA methods	>>>	49	Negative	68 %
	(5) LIA, ILMA	>>>	10	Negative	14 %
	(6) Immunoblotting	>>>	11	Negative	15 %
	(99) Another measurement principle	>>>	1	Negative	1,4 %
	Total per sample: n = 72 - Success: 100 % -				
B2	(1) Fluorescent methods	>>>	1	Negative	1,4 %
	(2) EIA methods	>>>	49	Negative	68 %
	(5) LIA, ILMA	>>>	10	Negative	14 %
	(6) Immunoblotting	>>>	11	Negative	15 %
	(99) Another measurement principle	>>>	1	Negative	1,4 %
	Total per sample: n = 72 - Success: 100 % -				
Total success: 100 %					
Set 3					
(580) Anti-ENA/SS-A/Ro-60					
A3	(2) EIA methods	>>>	29	Positive	39 %
	(5) LIA, ILMA	>>>	3	Positive	4,1 %
	(6) Immunoblotting		1	Negative	1,4 %
		>>>	39	Positive	53 %
	(99) Another measurement principle	>>>	2	Positive	2,7 %
	Total per sample: n = 74 - Success: 99 % -				
B3	(2) EIA methods	>>>	23	Negative	31 %
			2	Inconclusive result (borderline)	2,7 %
			4	Positive	5,4 %
	(5) LIA, ILMA	>>>	2	Negative	2,7 %
			1	Inconclusive result (borderline)	1,4 %
	(6) Immunoblotting	>>>	37	Negative	50 %
			2	Inconclusive result (borderline)	2,7 %
			1	Positive	1,4 %
	(99) Another measurement principle	>>>	2	Negative	2,7 %
	Total per sample: n = 74 - Success: 86 % -				
Total success: 85 %					
(581) Anti-ENA/SS-B/La					
A3	(2) EIA methods	>>>	27	Negative	36 %
			1	Positive	1,4 %
	(5) LIA, ILMA	>>>	3	Negative	4,1 %
	(6) Immunoblotting	>>>	36	Negative	49 %
			4	Inconclusive result (borderline)	5,4 %
			1	Positive	1,4 %
	(99) Another measurement principle	>>>	2	Negative	2,7 %
	Total per sample: n = 74 - Success: 92 % -				
B3	(2) EIA methods	>>>	28	Negative	38 %
	(5) LIA, ILMA	>>>	3	Negative	4,1 %
	(6) Immunoblotting	>>>	41	Negative	55 %
	(99) Another measurement principle	>>>	2	Negative	2,7 %
	Total per sample: n = 74 - Success: 100 % -				
Total success: 92 %					
(582) Anti-ENA/Scl-70					
A3	(2) EIA methods	>>>	28	Negative	38 %
	(5) LIA, ILMA	>>>	3	Negative	4,1 %
	(6) Immunoblotting	>>>	41	Negative	55 %
	(99) Another measurement principle	>>>	2	Negative	2,7 %
	Total per sample: n = 74 - Success: 100 % -				
B3	(2) EIA methods	>>>	28	Negative	38 %
	(5) LIA, ILMA	>>>	3	Negative	4,1 %
	(6) Immunoblotting	>>>	41	Negative	55 %
	(99) Another measurement principle	>>>	2	Negative	2,7 %
	Total per sample: n = 74 - Success: 100 % -				
Total success: 100 %					
(583) Anti-ENA/RNP					
A3	(2) EIA methods	>>>	27	Negative	36 %
			1	Inconclusive result (borderline)	1,4 %
	(5) LIA, ILMA	>>>	3	Negative	4,1 %
	(6) Immunoblotting	>>>	36	Negative	49 %
			5	Inconclusive result (borderline)	6,8 %

Summary statistics - qualitative results

(Groups: measurement principle)

EQA round: AIM2/20 - Autoimmunity

Deadline: 26.10.2020

Test Sample	Group		N	Result	N_{rel}
A3	(99) Another measurement principle	>>>	2	Negative	2,7 %
	Total per sample: n = 74	Success: 92 %			
B3	(2) EIA methods	>>>	28	Negative	38 %
	(5) LIA, ILMA	>>>	3	Negative	4,1 %
	(6) Immunoblotting	>>>	37	Negative	50 %
			2	Inconclusive result (borderline)	2,7 %
			2	Positive	2,7 %
	(99) Another measurement principle	>>>	2	Negative	2,7 %
	Total per sample: n = 74	Success: 95 %			
Total success: 86 %					

(584) Anti-ENA/Jo-1

A3	(2) EIA methods	>>>	28	Negative	38 %
	(5) LIA, ILMA	>>>	3	Negative	4,1 %
	(6) Immunoblotting	>>>	41	Negative	55 %
	(99) Another measurement principle	>>>	2	Negative	2,7 %
	Total per sample: n = 74	Success: 100 %			
B3	(2) EIA methods	>>>	28	Negative	38 %
	(5) LIA, ILMA	>>>	3	Negative	4,1 %
	(6) Immunoblotting	>>>	41	Negative	55 %
	(99) Another measurement principle	>>>	2	Negative	2,7 %
	Total per sample: n = 74	Success: 100 %			
Total success: 100 %					

(585) Anti-centromere antibodies

A3	(0) Not specified	>>>	1	Negative	1,5 %
	(1) Fluorescent methods	>>>	7	Negative	10 %
	(2) EIA methods	>>>	16	Negative	24 %
	(5) LIA, ILMA	>>>	2	Negative	2,9 %
	(6) Immunoblotting	>>>	41	Negative	60 %
	(99) Another measurement principle	>>>	1	Negative	1,5 %
	Total per sample: n = 68	Success: 100 %			
B3	(0) Not specified	>>>	1	Negative	1,5 %
	(1) Fluorescent methods	>>>	7	Negative	10 %
	(2) EIA methods	>>>	16	Negative	24 %
	(5) LIA, ILMA	>>>	2	Negative	2,9 %
	(6) Immunoblotting	>>>	41	Negative	60 %
	(99) Another measurement principle	>>>	1	Negative	1,5 %
	Total per sample: n = 68	Success: 100 %			
Total success: 100 %					

Set 4

(588) Anti-ds-DNA immunofluores. - prove

A4	(0) Not specified	>>>	56	Positive	100 %
	Total per sample: n = 56	Success: 100 %			
B4	(0) Not specified	>>>	56	Negative	100 %
	Total per sample: n = 56	Success: 100 %			
Total success: 100 %					

(577) Anti-ds-DNA immunofluor. - semi-quantity

A4	(0) Not specified	±	1	titre 10	1,9 %
		±	10	titre 80	19 %
		±	10	titre 160	19 %
		±	17	titre 320	32 %
		±	13	titre 640	25 %
		±	2	titre 1280	3,8 %
	Total per sample: n = 53	Success (only evaluated results): evaluation			
B4	(0) Not specified	±	36	titre 0 (not measurable)	68 %
		±	17	titre 10	32 %
	Total per sample: n = 53	Success (only evaluated results): evaluation			

(589) Anti-ds-DNA other methods

A4	(2) EIA methods	>>>	42	Positive	74 %
	(5) LIA, ILMA	>>>	7	Positive	12 %
	(6) Immunoblotting		1	Negative	1,8 %
			1	Inconclusive result (borderline)	1,8 %
		>>>	5	Positive	8,8 %
	(99) Another measurement principle	>>>	1	Positive	1,8 %
	Total per sample: n = 57	Success: 96 %			
B4	(2) EIA methods	>>>	42	Negative	74 %
	(5) LIA, ILMA	>>>	7	Negative	12 %

Summary statistics - qualitative results

(Groups: measurement principle)

EQA round: AIM2/20 - Autoimmunity

Deadline: 26.10.2020

Test

Sample	Group		N	Result	N_{rel}
B4	(6) Immunoblotting	>>>	7	Negative	12 %
	(99) Another measurement principle	>>>	1	Negative	1,8 %
	Total per sample: n = 57	Success: 100 %			

Total success: 96 %

Set 5

(591) Anti-nucleosomes IgG

A5	(2) EIA methods		1	Inconclusive result (borderline)	1,9 %
		>>>	37	Positive	70 %
	(6) Immunoblotting		1	Inconclusive result (borderline)	1,9 %
		>>>	14	Positive	26 %
	Total per sample: n = 53	Success: 96 %			
B5	(2) EIA methods	>>>	38	Negative	72 %
	(6) Immunoblotting		1	Not specified	1,9 %
		>>>	14	Negative	26 %
	Total per sample: n = 53	Success: 98 %			

Total success: 94 %

st_kl

End of report

Printed: 04.11.2020